This paper considers the problem of online calibration and recalibration of continuous glucose monitoring devices. A parametric relation between interstitial and blood glucose is investigated and a constructive algorithm to adaptively estimate the parameters within this relation is proposed. The algorithm explicitly considers measurement uncertainty of the device used to collect the calibration measurements and enables automatic detection of measurements which are not suitable to be used for calibration. The method was assessed on clinical data from 17 diabetic patients and the improvements with respect to the current state of the art is shown.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/EMBC.2013.6610402 | DOI Listing |
Diabetes Technol Ther
January 2025
Department of Paediatrics, University of Otago, Christchurch, New Zealand.
This study evaluated a next-generation automated insulin delivery (AID) algorithm for Omnipod in type 1 and type 2 diabetes across multiple phases: 14-day run-in with usual therapy, 48-h AID use in a hotel setting (type 1 only), and up to 6 weeks of outpatient AID use. Participants did, or did not, deliver manual boluses at alternating periods. Twelve adults with type 1 diabetes completed the hotel phase; 9 of those 12 plus 8 adults with type 2 diabetes completed the subsequent outpatient phase.
View Article and Find Full Text PDFDiabetes Technol Ther
January 2025
Senseonics, Incorporated, Germantown, Maryland, USA.
The implanted Eversense Continuous Glucose Monitoring (CGM) System transitioned from 90- to 180- to 365-day durations marketed today. This report summarizes the 365-day clinical study. ENHANCE was a prospective, multicenter study evaluating the accuracy and safety of the Eversense 365 CGM system through 1 year in adults with diabetes.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.
Aims: Currently, there is a lack of evidence regarding time in tight range (TITR) and long-term adverse outcomes. We aimed to investigate the association between TITR and the risk of all-cause and cardiovascular mortality among patients with type 2 diabetes.
Materials And Methods: A total of 6061 patients with type 2 diabetes were prospectively recruited in a single centre.
Diabetes Obes Metab
January 2025
Department of Endocrinology, Diabetes and Metabolism, University Children's Hospital, Ljubljana, Slovenia.
Aims: The aim of this study was to assess postprandial glycaemic outcomes using automated insulin delivery with faster acting insulin aspart (FIA) or standard insulin aspart (SIA) over 4 weeks in youth (aged 10-18 years) with type 1 diabetes.
Materials And Methods: We undertook a secondary analysis of postprandial glycaemic outcomes from a double-blind, randomised, crossover study comparing FIA to SIA using an investigational version of MiniMed™ 780G. Endpoints included postprandial time in tight range (70-140 mg/dL; TITR), postprandial glucose excursions and peak glucose, and incremental area under curve (iAUC).
Bioact Mater
April 2025
Joint Centre of Translational Medicine, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Hydrogel-based patches have demonstrated their values in diabetic wounds repair, particularly those intelligent dressings with continuous repair promoting and monitoring capabilities. Here, we propose a type of dual physiological responsive structural color particles for wound repair. The particles are composed of a hyaluronic acid methacryloyl (HAMA)-sodium alginate (Alg) inverse opal scaffold, filled with oxidized dextran (ODex)/quaternized chitosan (QCS) hydrogel.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!